Carla De Giovanni

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. pmc Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
    Carla De Giovanni
    Breast Cancer Res 16:R10. 2014
  2. doi A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome
    C De Giovanni
    Cancer Research Section, Department of Experimental Pathology, Alma Mater Studiorum, University of Bologna, I 40126 Bologna, Italy
    Hum Gene Ther 20:453-64. 2009
  3. ncbi Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
    Carla De Giovanni
    Department of Experimental Pathology, University of Bologna, Bologna
    Cancer Res 64:4001-9. 2004
  4. doi Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy
    Carla De Giovanni
    Department of Experimental Pathology, Alma Mater Studiorum University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Vaccine 27:2065-9. 2009
  5. ncbi Inhibition of prostate carcinogenesis by combined active immunoprophylaxis
    Carla De Giovanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 121:88-94. 2007
  6. ncbi Antimetastatic activity of a preventive cancer vaccine
    Patrizia Nanni
    Section of Cancer Research, University of Bologna, Bologna, Italy
    Cancer Res 67:11037-44. 2007
  7. doi High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, Viale Filopanti 22, University of Bologna, 40126 Bologna, Italy
    Eur J Cancer 46:659-68. 2010
  8. ncbi Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna
    Cancer Res 63:2728-32. 2003
  9. ncbi Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 105:384-9. 2003
  10. pmc Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma
    Annalisa Astolfi
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Am J Pathol 166:1205-16. 2005

Collaborators

Detail Information

Publications41

  1. pmc Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
    Carla De Giovanni
    Breast Cancer Res 16:R10. 2014
    ....
  2. doi A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome
    C De Giovanni
    Cancer Research Section, Department of Experimental Pathology, Alma Mater Studiorum, University of Bologna, I 40126 Bologna, Italy
    Hum Gene Ther 20:453-64. 2009
    ..In conclusion, the Tri-DNA vaccine is as effective as Triplex cell vaccine, exploiting a more restricted immune stimulation...
  3. ncbi Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
    Carla De Giovanni
    Department of Experimental Pathology, University of Bologna, Bologna
    Cancer Res 64:4001-9. 2004
    ..However, IL-12-engineered cell vaccine induced much lower circulating IL-12 and IFN-gamma, and therefore lower potential side effects and systemic toxicity...
  4. doi Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy
    Carla De Giovanni
    Department of Experimental Pathology, Alma Mater Studiorum University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Vaccine 27:2065-9. 2009
    ..These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention...
  5. ncbi Inhibition of prostate carcinogenesis by combined active immunoprophylaxis
    Carla De Giovanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 121:88-94. 2007
    ....
  6. ncbi Antimetastatic activity of a preventive cancer vaccine
    Patrizia Nanni
    Section of Cancer Research, University of Bologna, Bologna, Italy
    Cancer Res 67:11037-44. 2007
    ....
  7. doi High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, Viale Filopanti 22, University of Bologna, 40126 Bologna, Italy
    Eur J Cancer 46:659-68. 2010
    ..In conclusion, the Rag2(-/-);gammac(-/-) mouse model allowed the expression of human metastatic phenotypes inapparent in conventional immunodeficient mice and the preclinical testing of appropriate targeted therapies...
  8. ncbi Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna
    Cancer Res 63:2728-32. 2003
    ..Our findings led to the hypothesis that the interaction between HER family genes and the p53 pathway might be involved in the origin of human rhabdomyosarcoma...
  9. ncbi Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 105:384-9. 2003
    ..The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen...
  10. pmc Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma
    Annalisa Astolfi
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Am J Pathol 166:1205-16. 2005
    ..This gene expression analysis reveals the immune events associated with prevention of tumor development and shows that HER-2/neu transgenic mice represent a good model of a poor-prognosis group of human breast tumors...
  11. ncbi Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna, Italy
    Oncol Rep 18:451-6. 2007
    ..When used as a prophylactic vaccine, CCR7-transduced cell vaccine succeeded in the long-term control of mammary tumorigenesis in 25% of the HER-2/neu transgenic females, suggesting an increased immunogenicity of CCR7-engineered cells...
  12. ncbi Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis
    Stefania Croci
    Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Pathol Oncol Res 13:336-9. 2007
    ..Moreover, they expressed CCN2 protein at levels comparable to human rhabdomyosarcoma cells. Therefore BALBp53neu mice might be useful for the evaluation of the role played by CCN2 in rhabdomyosarcoma in vivo...
  13. ncbi Immunological prevention of a multigene cancer syndrome
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 64:8428-34. 2004
    ..A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues...
  14. ncbi Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    J Immunol 173:2288-96. 2004
    ..These findings show that inhibition of HER-2/neu carcinogenesis depends on cytokines and specific Abs, and that a highly effective vaccine can rescue Ab production even in B cell-deficient mice...
  15. doi In silico modeling and in vivo efficacy of cancer-preventive vaccinations
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 70:7755-63. 2010
    ..Our results show that an integrated in vivo-in silico approach could improve both mathematical and biological models of cancer immunoprevention...
  16. doi Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
    Patrizia Nanni
    Section of Cancer Research, Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
    Mol Cancer Ther 8:754-61. 2009
    ..Strategies to increase myogenin expression and block IL-4 could simultaneously reduce growth and migration, and enhance terminal differentiation of rhabdomyosarcoma, thus contributing to the control of tumor growth and metastatic spread...
  17. ncbi Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario
    Annalisa Astolfi
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, 40126, Italy
    Cancer Immunol Immunother 54:599-610. 2005
    ..Last, combination of the expression data with the protection results indicated that chronic vaccination is needed to maintain an active IFN-gamma-mediated response in the mammary gland...
  18. pmc Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus
    Patrizia Nanni
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    PLoS Pathog 9:e1003155. 2013
    ..Brain metastases were also reduced. Cumulatively, upon i.p. administration the HER-2-redirected oncolytic HSV effectively reduced the growth of ovarian and breast carcinoma disseminated to the peritoneal cavity...
  19. pmc Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor
    Patrizia Nanni
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    PLoS ONE 7:e39626. 2012
    ....
  20. ncbi Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Eur J Cancer 42:680-7. 2006
    ..Moreover ET-3 is present in plasma of mice bearing xenografts of human rhabdomyosarcoma cells, and may be potential new marker of the human rhabdomyosarcoma to be studied further...
  21. ncbi Cancer immunoprevention
    Pier Luigi Lollini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Future Oncol 1:57-66. 2005
    ..The success obtained in preclinical studies suggests that cancer immunoprevention should progress to clinical testing...
  22. ncbi Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity
    Carla De Giovanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 109:200-6. 2004
    ..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html...
  23. ncbi Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 64:1730-6. 2004
    ..CTGF emerges as a survival and differentiation factor and could be a new therapeutic target in human rhabdomyosarcoma...
  24. doi Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Proteomics 10:3835-53. 2010
    ..Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer...
  25. pmc Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
    Stefania Croci
    Laboratory of Immunology and Biology of Metastases, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Viale Filopanti 22, Bologna, 40126, Italy
    Breast Cancer Res 17:70. 2015
    ..Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role played by IL-15 in HER2/neu driven mammary carcinogenesis and in its immunoprevention...
  26. ncbi Vaccines and other immunological approaches for cancer immunoprevention
    Pier Luigi Lollini
    Department of Hematology and Oncological Sciences, University of Bologna, Italy
    Curr Drug Targets 12:1957-73. 2011
    ..The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans...
  27. pmc Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
    Laura Menotti
    Department of Experimental Pathology, Section on Microbiology and Virology, University of Bologna, Via San Giacomo 12, 40126 Bologna, Italy
    Proc Natl Acad Sci U S A 106:9039-44. 2009
    ....
  28. doi Rethinking herpes simplex virus: the way to oncolytic agents
    Gabriella Campadelli-Fiume
    Department of Experimental Pathology, Section on Microbiology and Virology, Alma Mater Studiorum University of Bologna, Italy
    Rev Med Virol 21:213-26. 2011
    ..A strategy to generate o-HSVs fully retargeted to human epidermal growth factor receptor-2 (HER-2) or other cancer-specific surface receptors is detailed...
  29. doi Preclinical vaccines against mammary carcinoma
    Pier Luigi Lollini
    Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Viale Filopanti 22, Bologna, Italy
    Expert Rev Vaccines 12:1449-63. 2013
    ..Translation to clinically effective vaccines will be fostered not only by new preclinical model systems, but also by the possibility to conduct veterinary vaccination trials in companion animals. ..
  30. ncbi Immunoprevention of colorectal cancer: a future possibility?
    Pier Luigi Lollini
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Gastroenterol Clin North Am 31:1001-14. 2002
    ..The design of a successful strategy for colorectal cancer will have to incorporate general concepts that have already been developed for dealing with other tumors, and intestine-specific immunologic strategies...
  31. ncbi The molecular basis of herpesviruses as oncolytic agents
    Laura Menotti
    Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Curr Pharm Biotechnol 13:1795-803. 2012
    ..They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants...
  32. doi Molecular and cellular biology of rhabdomyosarcoma
    Carla De Giovanni
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Bologna, Italy
    Future Oncol 5:1449-75. 2009
    ..This review matches recent molecular data with biological features of rhabdomyosarcoma. Alterations in molecular pathways, animal models, cell of origin and potential new therapeutic targets are discussed...
  33. ncbi Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 101:11-6. 2002
    ....
  34. pmc Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
    Lorena Landuzzi
    Laboratory of Experimental Oncology, Rizzoli Orthopedic Institute, Bologna, Italy PROMETEO Laboratory, STB, RIT Department, Rizzoli Orthopedic Institute, Bologna, Italy
    Oncotarget 5:11924-38. 2014
    ..Genetic prevention of lymphoma in p53 knockout mice led to new models of sarcoma development, available for studies on hemangiosarcoma and osteosarcoma onset and metastatization. ..
  35. doi Immunoprevention and immunotherapy of mammary carcinoma
    Pier Luigi Lollini
    Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
    Breast J 16:S39-41. 2010
    ..Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy...
  36. ncbi HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells
    Cinzia Ricci
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Italy
    J Immunother 25:314-23. 2002
    ..The toxic activity of anti-EGF-R immunotoxin was also observed on rhabdomyosarcoma cells expressing low level of EGF-R. EGF-R could be a novel therapeutic target of immunotoxins in human rhabdomyosarcoma...
  37. pmc Preclinical HER-2 Vaccines: From Rodent to Human HER-2
    Pier Luigi Lollini
    Laboratory of Immunology and Biology of Metastases, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Front Oncol 3:151. 2013
    ....
  38. ncbi The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus
    Antonio Rosato
    Department of Oncology and Surgical Sciences, University of Padova, Italy
    Cancer Res 63:2158-63. 2003
    ....
  39. ncbi Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice
    Elena Quaglino
    Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
    Cancer Res 64:2858-64. 2004
    ..These findings show that an appropriate vaccine effectively inhibits the progression of multifocal preneoplastic lesions...
  40. ncbi Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice
    Jay S Dela Cruz
    Department of Microbiology, The Molecular Biology Institute, University of California, 405 Hilgard Avenue, Los Angeles 90095 1489, USA
    Vaccine 21:1317-26. 2003
    ..Taken together these results suggest that vaccines including ECD(HER2) and Ab-cytokine fusion proteins may be used to elicit both humoral and cell-mediated responses against HER2/neu...
  41. pmc Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
    Elena Quaglino
    Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
    J Clin Invest 113:709-17. 2004
    ..This finding suggests that a new way can be found to secure the immunologic control of the progression of HER-2/neu preneoplastic lesions...